Grant Life Sciences, Inc. (fka GLIF)

[bepop12345]

Press Release Source: Grant Life Sciences Inc.

Grant Life Sciences Receives Cash Infusion
Thursday January 4, 9:23 am ET
"Taking in a relatively small amount of money--$400,000--at this time provides us with a short-term connection to what management hopes will be a much larger opportunity. Indeed, we believe our eagerness to announce this 'small' event should give our investors a sense of confidence about the longer-term prospects for Grant Life Sciences..."
Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist

LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences ('Grant') Inc. (OTC BB: GLIF - News) announced today that it has received a cash infusion of $400,000. The company intends to use this cash to fill outstanding orders for its products and continue validating its in-licensed diagnostic opportunities.

ADVERTISEMENT
"Taking in a relatively small amount of money--$400,000--at this time provides us with a short-term connection to what management hopes will be a much larger opportunity," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Indeed, we believe our eagerness to announce this 'small' event should give our investors a sense of confidence about the longer-term prospects for Grant Life Sciences, given the recent announcements which demonstrate that we are executing our new corporate strategy to: (1) acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels. We believe that this funding event underscores management's bullishness about Grant's prospects in this new year."

About Grant Life Sciences Inc.

Grant Life Sciences engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.


Contact:

Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO